Estrogen-Only vs. Combined HRT: What Determines the Choice?

Estrogen-Only vs. Combined HRT: How They Differ is a common question for people considering hormone replacement therapy (HRT) for menopausal symptoms. This article explains the main differences between estrogen-only and combined HRT, why the choice matters, and the factors clinicians use to decide which approach is right for an individual.

• Key takeaways
• Estrogen-only HRT contains estrogen alone and is typically used for people without a uterus; combined HRT includes estrogen plus a progestogen to protect the uterine lining.
• Uterine status (presence or absence of a uterus) is a primary factor guiding choice, but medical history, risks, and personal preferences also matter.
• Special circumstances (history of certain cancers, blood clots, or cardiovascular disease) often require specialist input and individualized care.

What are estrogen-only and combined HRT?

Estrogen-only HRT

Estrogen-only HRT provides one or more forms of estrogen to reduce menopausal symptoms such as hot flashes, night sweats, vaginal dryness, and some bone loss. Estrogen can be given as a pill, patch, gel, spray, or vaginal ring/crème. Because it supplies estrogen without a progestogen, it is generally prescribed only for people who do not have a uterus.

Combined HRT

Combined HRT pairs estrogen with a progestogen (a synthetic progestin or natural progesterone) to reduce the risk of abnormal thickening of the uterine lining (endometrial hyperplasia) and endometrial cancer that can occur with estrogen alone in people who still have a uterus. Combined HRT comes in several forms: continuous combined (both hormones every day), cyclic/sequential (estrogen daily with progestogen for part of the month), and various delivery methods such as pills, patches, or intrauterine systems.

Ingredients and intended use: How they differ

Estrogen types

Estrogens used in HRT include natural 17β-estradiol and synthetic conjugated estrogens. Delivery options influence side effects and local effects—vaginal estrogen products primarily treat local symptoms while systemic options address widespread menopausal effects.

Progestogens in combined HRT

Progestogens used in combined HRT can be natural progesterone or synthetic progestins. Each has different activity, side effect profiles, and impacts on mood, bleeding patterns, and possibly cardiovascular risk. For an overview of options and why a progestogen might be prescribed, see the role of progesterone in HRT.

Why uterine status matters

The single most important clinical factor when choosing between estrogen-only and combined HRT is whether a person has a uterus.

People with a uterus

When estrogen is given without a progestogen to someone with a uterus, the estrogen stimulates the endometrium (uterine lining). Over time this can cause abnormal growth and increase the risk of endometrial cancer. To prevent this, combined HRT or the use of a progestogen for at least part of each treatment cycle is standard care.

Guidance from professional bodies recommends that those who have an intact uterus should receive either continuous combined HRT (estrogen + progestogen daily) or sequential regimens that include progestogen for at least 10–14 days each month to protect the lining; more details about why protection matters are available in protecting the uterine lining.

People without a uterus (post-hysterectomy)

If the uterus has been removed, estrogen-only HRT is often a suitable option because there is no endometrium to be stimulated. For guidance on managing HRT after a hysterectomy, see HRT after hysterectomy. Even in this group, the wider medical history—like breast cancer risk or clotting history—matters when choosing the type, route, and dosage of estrogen.

Benefits, risks, and side effects

Common benefits

• Relief from vasomotor symptoms (hot flashes, night sweats).
• Improved sleep, mood, and quality of life for many people.
• Prevention of rapid bone loss and reduction in fracture risk with systemic estrogen.
• Vaginal estrogen can improve dryness, itching, pain with sex, and urinary symptoms with minimal systemic absorption when used locally.

Common side effects

• Breast tenderness, bloating, nausea, headaches, and mood changes.
• Spotting or irregular bleeding—more common in early months of combined or sequential regimens.
• Local irritation with transdermal or vaginal products in some people.

Serious risks and what evidence says

Major health risks associated with HRT have been studied extensively. Important points from consensus guidance include:

• Short- to medium-term use of HRT for symptom control is generally safe for many healthy people under age 60 or within 10 years of menopause, but individual risks vary.
• Combined HRT may be associated with a small increase in risk of breast cancer with longer-term use; the risk appears to depend on the type of progestogen and duration of therapy.
• Oral estrogen can modestly raise the risk of venous thromboembolism (blood clots); risk is lower with transdermal (patch or gel) routes.
• HRT may influence stroke and heart disease risk depending on age, timing of initiation, route of administration, and baseline cardiovascular risk.

Who should not use HRT or needs specialist review

Not everyone is a candidate for HRT. Common contraindications or situations requiring specialist care include:

• Current or recent breast cancer, or estrogen-sensitive cancers—this usually requires discussion with an oncologist before considering HRT.
• Unexplained vaginal bleeding—must be investigated before starting estrogen.
• History of active or recent blood clots (venous thromboembolism) or known thrombophilia—may require hematology input and favor non-estrogenic treatments or transdermal routes.
• Uncontrolled hypertension, liver disease, or recent stroke—needs careful assessment and specialist input.

Individual medical history and shared decision-making

Choosing between estrogen-only and combined HRT is part of shared decision-making between a person and their healthcare provider. This conversation should include a review of medical history, family history, symptom severity, treatment goals, and personal preferences.

Key history elements that influence choice

• Uterine status: presence of uterus typically requires combined HRT to protect the endometrium.
• Breast cancer risk: a strong family history or genetic risk may influence whether HRT is recommended and which type is used.
• Cardiovascular risk: age, smoking, blood pressure, cholesterol, and diabetes affect the balance of risks and benefits.
• History of blood clots: may steer clinicians toward transdermal routes or non-hormonal options.
• Other conditions: migraines with aura, liver disease, or active gallbladder disease may change the recommendation.

Personal preferences and quality of life

Many people prioritize rapid relief of hot flashes and improved sleep. Others prioritize minimizing long-term medication use or avoiding certain side effects like breast tenderness. Routes of administration (patch vs. pill vs. local vaginal therapy) and the convenience of dosing are commonly discussed when selecting a regimen.

Relevant exceptions and scenarios that change the typical approach

Hysterectomy with retained ovaries

People who have had a hysterectomy but still have ovaries may be offered estrogen-only HRT for menopausal symptom control and bone health. Decisions here also consider cancer risk factors and vascular history. See the section on HRT after hysterectomy for more details.

Endometrial abnormalities or history of endometrial hyperplasia

People with a history of endometrial hyperplasia usually need specialist input. In some cases, a progestogen-containing IUD can be used to protect the lining while allowing systemic estrogen, but this is individualized care and requires gynecologic assessment.

Breast cancer history

Current or recent breast cancer is generally a contraindication to systemic HRT. For those with a past history, decisions should be made in collaboration with oncology. Non-hormonal options may be recommended for symptom control.

High clotting risk

In people with a history of venous thromboembolism, transdermal estrogen (patch or gel) is sometimes considered because it has a lower impact on clotting factors than oral estrogen, but specialist advice is often needed. Non-hormonal treatments for hot flashes and bone health alternatives might also be discussed.

How clinicians monitor and adjust therapy

Initial assessment

Before starting HRT, clinicians typically take a focused history, check blood pressure, and assess baseline risk factors for heart disease, stroke, and clotting. They will review previous surgeries (like hysterectomy), cancer history, and family risks.

Follow-up and ongoing care

After initiating HRT, follow-up appointments are important to evaluate symptom control, side effects, bleeding patterns, and any new health concerns. For those on combined HRT who experience persistent or heavy bleeding, further investigation is needed. The team may change the regimen type, route, or progestogen choice based on effectiveness and tolerability.

Duration and reevaluation

There is no single recommended duration for HRT; it depends on symptom severity, age, evolving risk profile, and personal preference. Regular reevaluation—often annually—helps ensure the benefits continue to outweigh risks. Many guidelines suggest using the lowest effective dose for the shortest time needed, but for some people benefits of longer-term use may justify continued therapy after careful review.

When to seek specialist input

Refer to a menopause specialist, gynecologist, endocrinologist, cardiologist, hematologist, or oncologist when:

• There is complex past medical history (breast cancer, thrombosis, cardiovascular disease).
• Symptoms are severe or do not respond to first-line therapy.
• There are troublesome side effects or abnormal bleeding while on therapy.
• There is uncertainty about the best formulation or route due to competing risks.

Frequently Asked Questions

1. Can someone with a uterus ever take estrogen-only HRT?

No. People with an intact uterus usually need a progestogen alongside systemic estrogen to prevent endometrial hyperplasia and reduce the risk of endometrial cancer. Local vaginal estrogen alone may be used for urogenital symptoms but does not negate the need for protection if systemic estrogen is used.

2. Is combined HRT more likely to cause side effects than estrogen-only HRT?

Combined HRT can cause additional side effects related to the progestogen (such as mood changes or irregular bleeding), but individual experiences vary. The overall balance of benefits and risks depends on the person’s health profile and the specific hormones used.

3. If I had a hysterectomy, do I still need progestogen?

Generally no, because there is no uterine lining to protect. However, specialist advice may be needed if there are other concerns such as high breast cancer risk or complex medical history.

4. How does route of estrogen (pill vs. patch vs. gel) affect safety?

Transdermal (patch or gel) estrogen bypasses the liver and is associated with a lower impact on clotting factors and possibly a lower risk of venous thromboembolism compared with oral estrogen. Choice of route should be individualized based on risk factors and symptom pattern.

5. What if I’m worried about breast cancer risk—can I still use HRT?

Breast cancer risk is an important consideration. Short-term HRT may be acceptable for some people, but those with a high or current breast cancer risk should discuss alternatives and seek specialist input. The decision depends on personal risk factors, the severity of symptoms, and informed discussion with clinicians.

Conclusion

Choosing between estrogen-only and combined HRT depends most importantly on whether the uterus is present, but many other factors matter: age, timing of menopause, medical history, breast cancer and clotting risks, and personal priorities. Both types of HRT can offer meaningful relief from menopausal symptoms and protect bone health, but they come with potential side effects and risks that should be reviewed with a healthcare provider. If you are considering HRT or have questions about which regimen might suit you, talk with your clinician or a menopause specialist to develop a personalized plan based on current guidance and your individual needs.

---

Medical disclaimer: This article is for general educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Hormone therapy is not right for everyone. Always talk to your doctor or another qualified healthcare provider about your symptoms, health history and treatment options before starting, stopping or changing any medication.